Scholar Rock Holding Corporation SRRK

SRRK Company Overview

Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate protein growth factors within the transforming growth factor beta (TGF-β) superfamily. The company operates primarily in the biotechnology and rare disease sectors, with a strategic emphasis on neuromuscular disorders, cardiometabolic diseases, and other serious conditions involving dysregulated cellular signaling. Scholar Rock’s core scientific approach centers on selectively targeting latent growth factors before activation, a mechanism designed to improve therapeutic precision while reducing systemic side effects.

The company’s primary value driver is its pipeline of biologic therapies, particularly apitegromab, an investigational monoclonal antibody developed for spinal muscular atrophy (SMA). Scholar Rock was founded in 2012 and emerged from scientific research associated with protein signaling and growth factor biology. Since its initial public offering, the company has expanded its development capabilities through clinical partnerships, manufacturing arrangements, and ongoing investment in proprietary platform technologies intended to support multiple therapeutic candidates.